AU8215391A - Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor - Google Patents

Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor

Info

Publication number
AU8215391A
AU8215391A AU82153/91A AU8215391A AU8215391A AU 8215391 A AU8215391 A AU 8215391A AU 82153/91 A AU82153/91 A AU 82153/91A AU 8215391 A AU8215391 A AU 8215391A AU 8215391 A AU8215391 A AU 8215391A
Authority
AU
Australia
Prior art keywords
diagnostic
methods based
amyloid protein
beta amyloid
soluble derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU82153/91A
Inventor
Mark R Palmert
Steven G Younkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Case Western Reserve University
Original Assignee
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University filed Critical Case Western Reserve University
Publication of AU8215391A publication Critical patent/AU8215391A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU82153/91A 1990-06-29 1991-06-27 Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor Abandoned AU8215391A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54648590A 1990-06-29 1990-06-29
US546485 1990-06-29

Publications (1)

Publication Number Publication Date
AU8215391A true AU8215391A (en) 1992-01-23

Family

ID=24180644

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82153/91A Abandoned AU8215391A (en) 1990-06-29 1991-06-27 Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor

Country Status (2)

Country Link
AU (1) AU8215391A (en)
WO (1) WO1992000521A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010459A1 (en) * 1991-11-12 1993-05-27 The University Of Melbourne A method for assaying and treating alzheimer's disease
AU672379B2 (en) * 1992-04-09 1996-10-03 Bayer Corporation Diagnostic assay for Alzheimer's Disease based on the proteolysis of Alzheimer's precursor protein

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236682T5 (en) 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. TEST AND MODEL FOR ALZHEIMER'S DISEASE.
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
ES2203620T3 (en) * 1992-10-26 2004-04-16 Elan Pharmaceuticals, Inc. PROCEDURES FOR THE IDENTIFICATION OF INHIBITORS OF THE PRODUCTION OF THE BETA-AMILOID PEPTIDE.
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
AU7556994A (en) * 1993-08-13 1995-03-14 Molecular Geriatrics Corporation Methods for the diagnosis of alzheimer's disease
ATE198622T1 (en) 1993-10-27 2001-01-15 Elan Pharm Inc TRANSGENIC ANIMALS HOSTING APP ALLELES WITH THE SWEDISH MUTATION
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
FR2816411B1 (en) * 2000-11-03 2003-07-04 Inst Nat Sante Rech Med MEANS FOR DETECTING THE PATHOLOGICAL TRANSFORMATION OF THE APP PROTEIN AND THEIR APPLICATIONS
WO2010062904A2 (en) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010459A1 (en) * 1991-11-12 1993-05-27 The University Of Melbourne A method for assaying and treating alzheimer's disease
AU672379B2 (en) * 1992-04-09 1996-10-03 Bayer Corporation Diagnostic assay for Alzheimer's Disease based on the proteolysis of Alzheimer's precursor protein

Also Published As

Publication number Publication date
WO1992000521A1 (en) 1992-01-09

Similar Documents

Publication Publication Date Title
IL96946A0 (en) Boronic acid derivatives and diagnostic methods and kits incorporating the same
AU1317788A (en) Benzoxazole derivatives and preparation thereof
AU4249589A (en) Non-invasive inspection
AU8438991A (en) Probe system
AU8215391A (en) Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
AU7215287A (en) Amino-thiazole and oxazole derivatives
AU6182790A (en) Total-field imaging probe
AU3227789A (en) Procedure and arrangement for the measurement of revolutions
AU591020B2 (en) Omniaxis apparatus for processing particulates and the like
AU2995289A (en) Benzodioxole derivatives and processes for preparing the same
NO882940L (en) PROCEDURE FOR THE PREPARATION OF CASTANOSPERMINESTERS AND Glycosides.
IL98395A0 (en) Aminothiazole(iminooxyacetic acid)acetic acid derivatives and processes for preparing beta-lactams utilizing the same
AU3890689A (en) Human protein c mutants and method for preparing the same
AU569529B2 (en) Rooperol and derivatives
AU2501288A (en) Sialocylglycerolipids and method for preparing the same
AU1979888A (en) Oligosaccharide derivatives
AU7357887A (en) Dihydrorhodamines and halogenated derivatives thereof
AU8492591A (en) Method for the determination of the differential expression of mrna for the amyloid precursor protein (app)
AU4853690A (en) Cephalosporin derivatives and processes for their preparation
AU3153289A (en) Cephalosporin derivatives and processes for their preparation
AU7269987A (en) Thiazinone derivatives
AU3274189A (en) Probes
AU6824890A (en) Rifamycin derivatives and processes for the manufacture thereof
AR242635A1 (en) Procedure for the preparation of the ge 2270 antibiotic.
AU3989589A (en) Improved biosensor and the method of its use